Insulet Corp. (NSDQ:PODD) reported wider third-quarter losses than expected on Wall Street and lowered its full-year sales guidance, despite logging a 75.2 percent addition to the top line.
The Bedford, Mass.-based insulin pump maker posted losses of $13.6 million, or 29 cents per share, on sales of $44.6 million for the three months ended Sept. 30 – a 12.1 percent increase over net losses for the same period last year.
That’s sales growth of 75.2 percent compared with the $25.5 million Insulet reported during Q3 2010, when it posted losses of $12.1 million, or 30 cents per share.
Sign up to get our free newsletters delivered straight to your inbox
“Demand for the OmniPod insulin pump continued to grow in the third quarter, both in the U.S. and abroad,” president & CEO Duane DeSisto said in prepared remarks. “In addition to increased traction by our U.S. salesforce, our international partners continue to drive growth, including in Canada, where the OmniPod was launched in September. We are working diligently with the FDA to obtain clearance for the next generation OmniPod in the coming months. The smaller, lighter OmniPod will be another advance in our mission to improve the lives of people with diabetes.”
Insulet said it now expects full-year 2011 sales of between $150 million and $154 million, down from prior estimates of $152 million to $158 million.
ArthroCare’s Q3 sales slip, earnings plummet
Third quarter sales for ArthroCare Corp. (NSDQ:ARTC) slid 3.7 percent and net income plummeted 81.4 percent.
ArthroCare reported profits of $1.6 million, or 5 cents per share, on sales of $83.3 million for the three months ended Sept. 30.
That compares with profits of $8.4 million, or 25 cents per share, on sales of $86.5 million during the same period last year. Read more
Hansen Medical boosts sales, cuts Q3 losses
Hansen Medical (NSDQ:HNSN) boosted sales by 53.2 percent and cut losses by 16.4 percent during the third quarter.
Hansen posted losses of $10.1 million, or 18 cents per share, on sales of $5.4 million during the three months ended Sept. 30.
That compares with losses of $12.1 million, or 23 cents per share, on sales of $3.5 million during the same period last year. Read more
Cardiovascular Systems’s Q1 sales rise, losses narrow
Cardiovascular Systems (NSDQ:CSII) narrowed its first-quarter losses by nearly 10 percent and added 2.7 percent to its top line.
CSII logged a net loss of $3.9 million, or 22 cents per share, on sales of $18.7 million for the three months ended Sept. 30.
That compares with losses of $4.3 million, or 28 cents per share, on sales of $18.2 million during the same period last year. Read more
DexCom’s Q3 sales surge, losses tick lower
DexCom (NSDQ:DXCM) increased its third-quarter sales by 56.5 percent and narrowed losses by nearly 1 percent.
DexCom reported losses of $13.3 million, or 20 cents per share, on sales of $18.3 million for the three months ended Sept. 30.
That compares with losses of $13.4 million, or 23 cents per share, on sales of $11.7 million during the same period last year.
Read more
Theragenics nearly doubles Q3 profits
Theragenics (NYSE:TGX) nearly doubled its third-quarter profits and increase sales by 3.2 percent.
The company reported profits of $1.1 million, or 3 cents per share, on sales of $21.1 million for the three months ended Sept. 30.
That compares with profits of $771,000, or 2 cents per share, on sales of $20.4 million during the same period last year. Read more
Rockwell Medical’s losses soar, profits plunge
Third-quarter losses for Rockwell Medical (NSDQ:RMTI) soared a whopping 578.2 percent as sales plunged 18.8 percent.
Rockwell reported losses of $5.0 million, or 28 cents per share, on sales of $12.0 million for the three months ended Sept. 30.
That compares with losses of $743,000, or 4 cents per share, on sales of $14.7 million during the same period last year. Read more
Symmetry Medical’s sales, profits decline
Sales declined 8.2 percent and profits dropped 85.1 percent for Symmetry Medical (NYSE:SMA) during the third quarter.
Symmetry reported profits of $527,000, or 1 cent per share, on sales of $84.0 million during the three months ended Oct. 1.
That compares with profits of $3.5 million, or 10 cents per share, on sales of $91.5 million during the same period last year. Read more
Zynex raises Q3 sales, profits
Zynex (OTC:ZYXI) raised sales by 41.6 percent and incrased profits by 60.6 percent during the third quarter.
The company posted profits of $591,000, or 2 cents per share, on sales of $9.4 million for the three months ended Sept. 30.
That compares with profits of $368,000, or 1 cent per share, on sales of $6.7 million during the same period last year. Read more
